Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population

Rhyne, Danielle N.; Anderson, Sarah L.; Gedde, Margaret; Borgelt, Laura M.

doi:10.1002/phar.1673

Cited by 73 publications

(70 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The medical literature regarding treatment of headache, migraine, and facial pain disorders shows supporting evidence for cannabis/cannabinoids in the treatment of chronic headaches, migraine including chronic migraine, medication overuse headache, cluster headache, idiopathic intracranial hypertension, and multiple sclerosis (MS) associated trigeminal neuralgia . At the time of this writing, this majority of supporting literature consists primarily of case series, case studies, case reports, surveys, clinical/anecdotal reports, and one retrospective analysis.…”

Section: Cannabis and Cannabinoids In Migraine Headache And Facial mentioning

confidence: 99%

See 1 more Smart Citation

Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

2018

View full text Add to dashboard Cite

There is accumulating evidence for various therapeutic benefits of cannabis/cannabinoids, especially in the treatment of pain, which may also apply to the treatment of migraine and headache. There is also supporting evidence that cannabis may assist in opioid detoxification and weaning, thus making it a potential weapon in battling the opioid epidemic. Cannabis science is a rapidly evolving medical sector and industry with increasingly regulated production standards. Further research is anticipated to optimize breeding of strain-specific synergistic ratios of cannabinoids, terpenes, and other phytochemicals for predictable user effects, characteristics, and improved symptom and disease-targeted therapies.

show abstract

Section: Cannabis and Cannabinoids In Migraine Headache And Facial mentioning

confidence: 99%

“…There has been one retrospective study of cannabis use in the treatment of migraine, and it was strongly positive, although limitations exist . In this study, the investigators reviewed charts of 121 adults from 2 medical marijuana specialty clinics in Colorado.…”

Section: Cannabis and Cannabinoids In Migraine Headache And Facial mentioning

confidence: 99%

Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

2018

View full text Add to dashboard Cite

show abstract

“…It would be interesting to explore whether migraine, anxiety and sleep disorders in patients with rare deleterious variants in CNR1 could be alleviated by treatment with THC or other CB1 agonists that may effectively stimulate the impaired and/or remaining functional CB1 receptors. In this regard, we note that a recent observational study of 121 adults with migraine reported a decrease in mean headache frequency from 10.4 to 4.6 headaches per month (p<0.0001) for patients receiving medicinal cannabis [71].…”

Section: Based On Exac Gene Constraint Valuesmentioning

confidence: 67%

Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans

Smith

Stanley

Foss

et al. 2017

Preprint

View full text Add to dashboard Cite

Rare genetic variants in the core endocannabinoid system genes CNR1, CNR2, DAGLA, MGLL and FAAH were identified in molecular testing data from up to 6.032 patients with a broad spectrum of neurological disorders. The variants were evaluated for association with phenotypes similar to those observed in the orthologous gene knockouts in mice. Heterozygous rare coding variants in CNR1, which encodes the type 1 cannabinoid receptor (CB1), were found to be significantly associated with pain sensitivity (especially migraine), sleep and memory disorders -alone or in combination with anxiety -compared to a set of controls without such CNR1 variants. Similarly, heterozygous rare variants in DAGLA, which encodes diacylglycerol lipase alpha, were found to be significantly associated with seizures and developmental disorders, including abnormalities of brain morphology, compared to controls. Rare variants in MGLL, FAAH and CNR2 were not associated with any neurological phenotypes in the patients tested. Diacylglycerol lipase alpha synthesizes the endocannabinoid 2-AG in the brain, which interacts with CB1 receptors. The phenotypes associated with rare CNR1 variants are reminiscent of those implicated in the theory of clinical endocannabinoid deficiency syndrome. The severe phenotypes associated with rare DAGLA variants underscore the critical role of rapid 2-AG synthesis and the endocannabinoid system in regulating neurological function and development. Mapping of the variants to the 3D structure of the type 1 cannabinoid receptor, or primary structure of diacylglycerol lipase alpha, reveals clustering of variants in certain structural regions and is consistent with impacts to function.

show abstract

“…These studies suggest the efficacy and interactions of cannabis or THC with the eCB may be dependent on usage, as well as final potency of the CBs. A recent retrospective study found medical marijuana to effectively reduce the frequency of headaches in patients, however, various side-effects were reported depending on the type of marijuana [109]. In regard to migraine pain, THC stimulates 5-HT synthesis [110], is a 5HT1A agonist, and 5HT3 antagonist implicating its role in the treatment of migraine and pain with several other potential mechanisms of action [111].…”

Section: Phytocannabinoidsmentioning

confidence: 99%

Understanding the endocannabinoid system as a modulator of the trigeminal pain response to concussion

et al. 2017

View full text Add to dashboard Cite

Post-traumatic headache is the most common symptom of postconcussion syndrome and becomes a chronic neurological disorder in a substantial proportion of patients. This review provides a brief overview of the epidemiology of postconcussion headache, research models used to study this disorder, as well as the proposed mechanisms. An objective of this review is to enhance the understanding of how the endogenous cannabinoid system is essential for maintaining the balance of the CNS and regulating inflammation after injury, and in turn making the endocannabinoid system a potential modulator of the trigeminal response to concussion. The review describes the role of endocannabinoid modulation of pain and the potential for use of phytocannabinoids to treat pain, migraine and concussion.

show abstract

Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population

Cited by 73 publications

References 9 publications

Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans

Understanding the endocannabinoid system as a modulator of the trigeminal pain response to concussion

Contact Info

Product

Resources

About